Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
4.910
+0.380 (8.39%)
At close: Sep 18, 2025, 4:00 PM EDT
4.930
+0.020 (0.41%)
After-hours: Sep 18, 2025, 6:20 PM EDT
Precision BioSciences Revenue
Precision BioSciences had revenue of $18.00K in the quarter ending June 30, 2025, a decrease of -99.96%. This brings the company's revenue in the last twelve months to $1.26M, down -98.56% year-over-year. In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth.
Revenue (ttm)
$1.26M
Revenue Growth
-98.56%
P/S Ratio
34.71
Revenue / Employee
$11,676
Employees
108
Market Cap
57.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DTIL News
- 2 days ago - Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 6 days ago - Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium - Business Wire
- 10 days ago - Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status - Business Wire
- 6 weeks ago - Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B - Business Wire
- 6 weeks ago - Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 - Business Wire
- 2 months ago - Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
- 2 months ago - Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire